エルラナタマブ（遺伝子組換え）
Elranatamab (Genetical Recombination)


エルラナタマブは，B細胞成熟抗原（BCMA）及びCD3ε鎖に対する遺伝子組換え二重特異性モノクローナル抗体であり，抗BCMA抗体はヒトIgG2に由来し，抗CD3ε抗体の相補性決定部はマウス抗体に，その他はヒトIgG2に由来する．抗BCMA-H鎖の6つのアミノ酸残基が置換（C218E，P223E，D259A，A324S，P325S，L362E）されている．また，抗CD3ε-H鎖の7つのアミノ酸残基が置換（C224R，E226R，P229R，D265A，A330S，P331S，K409R）されている．エルラナタマブは，CHO細胞により産生される．エルラナタマブは，441個のアミノ酸残基からなる抗BCMA-H鎖（γ2鎖）1本，447個のアミノ酸残基からなる抗CD3ε-H鎖（γ2鎖）1本，215個のアミノ酸残基からなる抗BCMA-L鎖（κ鎖）1本及び219個のアミノ酸残基からなる抗CD3ε-L鎖（κ鎖）1本で構成される糖タンパク質（分子量：約149,000）である．

Elranatamab is a recombinant bispecific monoclonal antibody against B-cell maturation antigen (BCMA) and CD3ε chain, which is composed of anti-BCMA antibody derived from human IgG2, and anti-CD3ε antibody whose complementarity-determining regions are derived from mouse antibody and other regions are derived from human IgG2. In the anti-BCMA-H-chain, the amino acid residues are substituted at 6 positions (C218E, P223E, D259A, A324S, P325S, L362E). In the anti-CD3ε-H-chain, the amino acid residues are substituted at 7 positions (C224R, E226R, P229R, D265A, A330S, P331S, K409R). Elranatamab is produced in CHO cells. Elranatamab is a glycoprotein (molecular weight: ca. 149,000) composed of an anti-BCMA-H-chain (γ2-chain) consisting of 441 amino acid residues, an anti-CD3ε-H-chain (γ2-chain) consisting of 447 amino acid residues, an anti-BCMA-L-chain (κ-chain) consisting of 215 amino acid residues, and an anti-CD3ε-L-chain (κ-chain) consisting of 219 amino acid residues.

[2408850-14-4]